A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Trial Profile

A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Eye disorders
  • Focus Therapeutic Use
  • Acronyms OASIS
  • Sponsors ThromboGenics
  • Most Recent Events

    • 16 Aug 2017 Results from this trial were presented at the 35th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), according to a ThromboGenics media release.
    • 02 Nov 2016 Long-term efficacy results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 Sep 2016 Results from this trial will be presented at the EURETINA Annual Conference 2016, according to a ThromboGenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top